查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1468354

2024-2032年依类型（盐酸多柔比星、舒尼替尼、多西他赛、丝裂霉素、氟尿嘧啶、伊马替尼、曲妥珠单抗）、给药途径（口服、肠胃外）、最终用户（医院、诊所等）和地区的胃癌药物市场报告

Gastric Cancer Drugs Market Report by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球胃癌药物市场规模达46亿美元。慢性和急性适应症盛行率的上升、与体重相关的健康问题的发生率不断上升以及健康意识的增强是推动市场发展的一些关键因素。

胃癌药物是为了缓解或治疗被诊断出患有胃癌（胃内壁形成恶性细胞）的患者而开发的药物。胃癌的一些常见症状是不明原因的体重减轻、消化不良、腹胀、噁心、呕吐、胃灼热和吞嚥食物困难。盐酸阿霉素、舒尼替尼、丝裂霉素、氟尿嘧啶、伊马替尼和多西他赛是常用的胃癌药物。它们透过杀死一些癌细胞来帮助缩小肿瘤并缓解癌症的迹象和症状。它们还有助于减少癌细胞的生长、分裂和产生更多细胞。因此，胃癌药物透过口服和肠胃外形式给药，并由医院、诊所和特殊治疗中心使用。

全球老年人口的增加和肥胖症的盛行率上升主要推动了市场的成长。与此一致的是，由于不健康的饮食习惯和久坐的生活方式，与体重相关的健康问题的发生率不断增加，有利于市场的成长。此外，由于烟草製品和酒精饮料的消费增加，癌症病例不断增加，以及对预防和治疗药物的需求增加，是另一个促进生长的因素。除此之外，两种有助于消除肿瘤生长的胃癌生物标记的推出也为市场成长提供了动力。此外，製造商正专注于创造副作用最小的产品变体，例如胃糜烂和噁心，从而推动市场成长。同时，专注于开发有效和特异性癌症治疗方法的快速技术进步正在为市场创造积极的前景。此外，领先的製药公司和主要参与者正在大力投资研发 (R&D) 活动，以开发更安全、更有效、经济上可行且更易于管理的胃癌药物。除此之外，政府实施各种促进药品製造、加工和包装的倡议，确保製造商生产的药品质量，对市场成长有正面影响。其他因素，包括医疗保健支出的增加以及消费者对胃癌症状和可用治疗方案的认识不断增强，预计将推动市场成长。

本报告回答的关键问题：

  • 迄今为止，全球胃癌药物市场表现如何，未来几年将如何表现？
  • 全球胃癌药物市场的驱动因素、限制因素和机会是什么？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的胃癌药物市场？
  • 依类型划分市场是怎么样的？
  • 根据给药途径，市场的分化为何？
  • 基于最终用户的市场区隔是什么？
  • 全球胃癌药物市场竞争格局如何？
  • 全球胃癌药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球胃癌药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 盐酸阿霉素
    • 市场走向
    • 市场预测
  • 舒尼替尼
    • 市场走向
    • 市场预测
  • 多西紫杉醇
    • 市场走向
    • 市场预测
  • 丝裂霉素
    • 市场走向
    • 市场预测
  • 氟尿嘧啶
    • 市场走向
    • 市场预测
  • 伊马替尼
    • 市场走向
    • 市场预测
  • 曲妥珠单抗
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依管理途径

  • 口服
    • 市场走向
    • 市场预测
  • 注射用
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 诊所
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Arog Pharamaceuticals Inc.
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Eli Lilly and company
    • F. Hoffmann-La Roche AG
    • Ono Pharmaceutical Co. Ltd.
    • Sanofi SA
    • Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
Product Code: SR112024A6648

The global gastric cancer drugs market size reached US$ 4.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 11.26% during 2024-2032. The rising prevalence of chronic and acute indications, growing incidences of weight-related health concerns, and increasing health consciousness represent some of the key factors driving the market.

Gastric cancer drugs are medications developed to relieve or treat an individual diagnosed with stomach cancer in which malignant cells form in the lining of the stomach. Some common symptoms of gastric cancer are unexplained weight loss, indigestion, bloating, nausea, vomiting, heartburn, and difficulty swallowing food. Doxorubicin hydrochloride, sunitinib, mitomycin, fluorouracil, imatinib, and docetaxel are commonly available gastric cancer drugs. They help to shrink a tumor and relieve signs and symptoms of cancer by killing some of the cancer cells. They also assist in reducing cancer cells from growing, dividing, and making more cells. As a result, gastric cancer drugs are administered through oral and parenteral forms and are used by hospitals, clinics, and special treatment centers.

The increasing geriatric population and the rising prevalence of obesity across the globe are primarily driving the market growth. In line with this, the growing incidences of weight-related health concerns due to unhealthy eating habits and sedentary lifestyles are favoring the market growth. Moreover, the increasing cases of cancer, due to the rising consumption of tobacco-based products and alcoholic beverages, and the enhanced need need for preventive and therapeutic medications are acting as another growth-inducing factor. Apart from this, the introduction of two gastric cancer biomarkers that help in eliminating tumor growth is providing an impetus to the market growth. Moreover, manufacturers are focusing on creating product variants with minimal side effects, such as gastric erosion and nausea, thus propelling the market toward growth. Along with this, rapid technological advancements focusing on the development of effective and specific cancer treatments are creating a positive outlook for the market. Furthermore, leading pharmaceutical companies and key players are investing heavily in research and development (R&D) activities to develop gastric cancer drugs that are safer, more effective, economically viable, and easier to administer. Besides this, the implementation of various government initiatives to promote the manufacturing, processing, and packing of a drug product ensuring the quality of drugs produced by manufacturers is positively influencing the market growth. Other factors, including rising healthcare expenditure and growing consumer awareness regarding the symptoms and the available treatment options for gastric cancer, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global gastric cancer drugs market, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, route of administration, and end user.

Type Insights

Doxorubicin Hydrochloride

Sunitinib

Docetaxel

Mitomycin

Fluorouracil

Imatinib

Trastuzumab

The report has provided a detailed breakup and analysis of the gastric cancer drugs market based on the type. This includes doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. According to the report, trastuzumab represented the largest segment.

Route of Administration Insights

Oral

Parenteral

A detailed breakup and analysis of the gastric cancer drugs market based on the route of administration has also been provided in the report. This includes oral and parenteral. According to the report, parenteral accounted for the largest market share.

End User Insights

Hospitals

Clinics

Others

The report has also provided a detailed breakup and analysis of the gastric cancer drugs market based on the end user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest segment.

Regional Insights

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, Asia Pacific was the largest market for gastric cancer drugs. Some of the factors driving the Asia Pacific gastric cancer drugs market included its high healthcare expenditure, technological advancements, and rising geriatric population.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global gastric cancer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Arog Pharamaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global gastric cancer drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global gastric cancer drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive gastric cancer drugs market?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on end user?
  • What is the competitive structure of the global gastric cancer drugs market?
  • Who are the key players/companies in the global gastric cancer drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastric Cancer Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Doxorubicin Hydrochloride
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Sunitinib
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Docetaxel
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mitomycin
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Fluorouracil
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Imatinib
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Trastuzumab
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parenteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arog Pharamaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Daiichi Sankyo Company Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ono Pharmaceutical Co. Ltd.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Sanofi S.A.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

List of Figures

  • Figure 1: Global: Gastric Cancer Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastric Cancer Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Gastric Cancer Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Gastric Cancer Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Gastric Cancer Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Gastric Cancer Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Gastric Cancer Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Gastric Cancer Drugs (Sunitinib) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Gastric Cancer Drugs (Sunitinib) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Gastric Cancer Drugs (Docetaxel) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Gastric Cancer Drugs (Docetaxel) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Gastric Cancer Drugs (Mitomycin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Gastric Cancer Drugs (Mitomycin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Gastric Cancer Drugs (Fluorouracil) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Gastric Cancer Drugs (Fluorouracil) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Gastric Cancer Drugs (Imatinib) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Gastric Cancer Drugs (Imatinib) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Gastric Cancer Drugs (Trastuzumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Gastric Cancer Drugs (Trastuzumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Gastric Cancer Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Gastric Cancer Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Gastric Cancer Drugs (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Gastric Cancer Drugs (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Gastric Cancer Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Gastric Cancer Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Gastric Cancer Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Gastric Cancer Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Gastric Cancer Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Gastric Cancer Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Gastric Cancer Drugs Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Gastric Cancer Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Gastric Cancer Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Gastric Cancer Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastric Cancer Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Gastric Cancer Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Gastric Cancer Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Gastric Cancer Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Gastric Cancer Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Gastric Cancer Drugs Market: Competitive Structure
  • Table 7: Global: Gastric Cancer Drugs Market: Key Players